Mitochondrial respiration - an important therapeutic target in melanoma

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Barbi de Moura, Michelle ^a   Vincent, Garret ^a   Fayewicz, Shelley L ^a   Bateman, Nicholas W ^a   Hood, Brian L ^b   Sun, Mai ^c   Suhan, Joseph ^d   Duensing, Stefan ^e   Yin, Yan ^a   Sander, Cindy ^a   Kirkwood, John M ^a   Becker, Dorothea ^a   Conrads, Thomas P ^b   van Houten, Bennett ^a   Moschos, Stergios J ^a,f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d CARNEGIE MELLON UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELESCLOMOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL DISRUPTION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG TARGETING; GLYCOLYSIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; MELANOCYTE; MELANOMA CELL; METASTATIC MELANOMA CELL; MITOCHONDRIAL RESPIRATION; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN ANALYSIS; STABLE ISOTOPE LABELING WITH AMINO ACID IN CELL CULTURE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL RESPIRATION; GLYCOLYSIS; HUMANS; HYDRAZINES; MELANOMA; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84865094467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040690     Document Type: Article

References (47)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine 364: 2507-2516.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
3. Eberle J, Hossini AM, (2008) Expression and function of bcl-2 proteins in melanoma. Curr Genomics 9: 409-419.
4. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE, (2009) Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7: 549-556.
5. Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, et al. (2010) Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol 23: 45-53.
6. Meyskens FL Jr, Farmer P, Fruehauf JP, (2001) Redox regulation in human melanocytes and melanoma. Pigment Cell Res 14: 148-154.
7. de Moura MB, dos Santos LS, Van Houten B, (2010) Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 51: 391-405.
8. Nakajima EC, Van Houten B (2012) Metabolic symbiosis in cancer: Refocusing the Warburg lens. Mol Carcinog Jan 6 [Epub ahead of print].
9. Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, et al. (2008) Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7: 2319-2327.
10. Foley KP, Bertin J, Chan K, Inoue T, Kirshner JR, et al. (2007) The oxidative stress inducer STA-4783 enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models (abstr A290). AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics San Francisco, CA.
11. O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, et al. (2009) Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 27: 5452-5458.
12. Hauschild A, Eggermont AM, Jacobson E, O'Day SJ. (2009) Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (LBA9012). ASCO Annual Meeting Orlando, Fl.
13. Manola J, Atkins M, Ibrahim J, Kirkwood J, (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18: 3782-3793.
14. Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, et al. (2003) Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 16: 273-279.
15. Ganter B, Giroux CN, (2008) Emerging applications of network and pathway analysis in drug discovery and development. Curr Opin Drug Discov Devel 11: 86-94.
16. Brand MD, (2010) The sites and topology of mitochondrial superoxide production. Exp Gerontol 45: 466-472.
17. Jonas EA, Hickman JA, Chachar M, Polster BM, Brandt TA, et al. (2004) Proapoptotic N-truncated BCL-xL protein activates endogenous mitochondrial channels in living synaptic terminals. Proc Natl Acad Sci U S A 101: 13590-13595.
18. McConnell HM, Owicki JC, Parce JW, Miller DL, Baxter GT, et al. (1992) The cytosensor microphysiometer: biological applications of silicon technology. Science 257: 1906-1912.
19. Parce JW, Owicki JC, Kercso KM, Sigal GB, Wada HG, et al. (1989) Detection of cell-affecting agents with a silicon biosensor. Science 246: 243-247.
20. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, et al. (2011) Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A 108: 16062-16067.
21. Hill BG, Dranka BP, Zou L, Chatham JC, Darley-Usmar VM, (2009) Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. Biochem J 424: 99-107.
22. Huttemann M, Lee I, Pecinova A, Pecina P, Przyklenk K, et al. (2008) Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J Bioenerg Biomembr 40: 445-456.
23. Birket MJ, Orr AL, Gerencser AA, Madden DT, Vitelli C, et al. (2011) A reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells. J Cell Sci 124: 348-358.
24. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, et al. (2007) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292: C125-136.
25. Qian W, Van Houten B, (2010) Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods 51: 452-457.
26. Hersey P, Watts RN, Zhang XD, Hackett J, (2009) Metabolic approaches to treatment of melanoma. Clin Cancer Res 15: 6490-6494.
27. Vander Heiden MG, (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
28. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
29. Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, et al. (2012) Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One 7: e29798.
30. Gnaiger E, Lassnig B, Kuznetsov A, Rieger G, Margreiter R, (1998) Mitochondrial oxygen affinity, respiratory flux control and excess capacity of cytochrome c oxidase. J Exp Biol 201: 1129-1139.
31. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, et al. (2012) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481: 380-384.
32. Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW, (2012) Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 25: 375-383.
33. Buchet K, Godinot C, (1998) Functional F1-ATPase essential in maintaining growth and membrane potential of human mitochondrial DNA-depleted rho degrees cells. J Biol Chem 273: 22983-22989.
34. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
35. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, et al. (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49: 3759-3764.
36. Berridge MV, Tan AS, (2010) Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res 13: 139-141.
37. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, et al. (2011) Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 286: 42626-42634.
38. Kong Q, Beel JA, Lillehei KO, (2000) A threshold concept for cancer therapy. Med Hypotheses 55: 29-35.
39. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK, (2010) Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 46: 1159-1169.
40. Semenza GL, (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56.
41. Wang X, Katayama A, Wang Y, Yu L, Favoino E, et al. (2011) Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 71: 7410-7422.
42. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, et al. (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8: 39.
43. Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, et al. (2012) Antitumor activity of vemurafenib in previously treated patients with BRAFV600 mutated metastatic melanoma (BRIM2). N Engl J Med 366: 707-714.
44. Silverthorn CF, Alani RM, (2010) Glyceraldehyde-3-phosphate dehydrogenase expression is altered by hypoxia in melanoma cells and primary human melanocytes. Melanoma Res 20: 61-63.
45. Flint MS, Kim G, Hood BL, Bateman NW, Stewart NA, et al. (2009) Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway. Psychoneuroendocrinology 34: 1533-1541.
46. Moschos SJ, Dodd NR, Jukic DM, Fayewicz SL, Wang X, et al. (2009) Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation. Cancer Biol Ther 8: 1815-1825.
47. Dykstra KM, Pokusa JE, Suhan J, Lee TH, (2010) Yip1A structures the mammalian endoplasmic reticulum. Mol Biol Cell 21: 1556-1568.